Long-Term Outcomes Among a Nationwide Cohort of Patients Using an Implantable Cardioverter-Defibrillator: UMBRELLA Study Final Results.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
05 01 2021
Historique:
pubmed: 29 12 2020
medline: 21 10 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

Background Large-scale studies describing modern populations using an implantable cardioverter-defibrillator (ICD) are lacking. We aimed to analyze the incidence of arrhythmia, device interventions, and mortality in a broad spectrum of real-world ICD patients with different heart disorders. Methods and Results The UMBRELLA study is a prospective, multicenter, nationwide study of contemporary patients using an ICD followed up by remote monitoring, with a blinded review of arrhythmic episodes. From November 2005 to November 2017, 4296 patients were followed up. After 46.6±27.3 months, 16 067 episodes of sustained ventricular arrhythmia occurred in 1344 patients (31.3%). Appropriate ICD therapy occurred in 27.3% of study population. Patients with ischemic cardiomyopathy (hazard ratio [HR], 1.51; 95% CI, 1.29-1.78), dilated cardiomyopathy (HR, 1.28; 95% CI, 1.07-1.53), and valvular heart disease (HR, 1.94; 95% CI, 1.43-2.62) exhibited a higher risk of appropriate ICD therapies, whereas patients with hypertrophic cardiomyopathy (HR, 0.72; 95% CI, 0.54-0.96) and Brugada syndrome (HR, 0.25; 95% CI, 0.14-0.45) showed a lower risk. All-cause death was 13.4% at follow-up. Ischemic cardiomyopathy (HR, 3.09; 95% CI, 2.58-5.90), dilated cardiomyopathy (HR, 3.33; 95% CI, 2.18-5.10), and valvular heart disease (HR, 3.97; 95% CI, 2.25-6.99) had the worst prognoses. Delayed high-rate detection was enabled in 39.7% of patients, and single-zone programming occurred in 52.6% of primary prevention patients. Both parameters correlated with lower risk of first appropriate ICD therapy, with no excess risk of mortality. The rate of inappropriate shocks at follow-up was low (6%) and did not differ among type of ICD but was lower in SmartShock-capable devices. Conclusions Irrespective of the cause, contemporary ICD patients with heart failure-related disorders had a similar risk of ICD life-saving interventions and death. Current ICD programming recommendations still need to be implemented. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NTC01561144.

Identifiants

pubmed: 33356406
doi: 10.1161/JAHA.120.018108
pmc: PMC7955463
doi:

Banques de données

ClinicalTrials.gov
['NCT01561144']

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e018108

Investigateurs

Ricardo Pavón (R)
José María Arizón (JM)
Miguel Álvarez López (M)
Javier Alzueta (J)
Ernesto Díaz Infante (E)
David Calvo (D)
Juan Carlos Rodríguez (JC)
Aníbal Rodríguez (A)
Luis Álvarez (L)
Juanjo Olalla (J)
Javier Jiménez Díaz (J)
Javier Balaguer (J)
Miguel Ángel Arias (MÁ)
Jerónimo Rubio (J)
Marisa Fidalgo (M)
Francisco-Javier García (FJ)
Xavier Viñolas (X)
Josep Brugada (J)
Ignasi Anguera (I)
Roger Villuendas (R)
Rosa Porro (R)
Joaquín Fernández de la Concha (J)
Luisa Pérez (L)
Enrique García Campo (E)
Ignacio Fernández Lozano (I)
Julián Villacastín (J)
Ángel Arenal (Á)
Roberto Muñoz Aguilera (R)
Antonio Hernández (A)
Rafael Peinado (R)
Arcadio García Alberola (A)
Fernando Pérez Lorente (F)
Nuria Basterra (N)
María Fe Arcocha (MF)
Andrés Bodegas (A)
Francisco Zumalde (F)
José B Martínez Ferrer (JB)
José María Porres (JM)
José Moreno Arribas (J)
Ricardo Ruiz (R)
Aurelio Quesada (A)
Juan Gabriel Martínez (JG)
María José Sancho-Tello (MJ)

Références

J Am Heart Assoc. 2017 Jun 6;6(6):
pubmed: 28588093
Rev Esp Cardiol (Engl Ed). 2016 Mar;69(3):272-8
pubmed: 26481284
Rev Esp Cardiol (Engl Ed). 2019 Dec;72(12):1054-1064
pubmed: 31727564
Heart Rhythm. 2015 May;12(5):926-36
pubmed: 25637563
Nat Rev Cardiol. 2010 Apr;7(4):216-25
pubmed: 20142817
Circulation. 2010 Sep 28;122(13):1272-82
pubmed: 20837891
JAMA. 2013 Jan 2;309(1):55-62
pubmed: 23280225
Europace. 2018 Jan 1;20(1):65-72
pubmed: 28082419
Heart. 2012 Jun;98(11):872-7
pubmed: 22581736
Eur Heart J. 2014 Aug 7;35(30):2010-20
pubmed: 24126876
Am J Cardiol. 2006 Apr 15;97(8):1255-61
pubmed: 16616037
N Engl J Med. 2016 Sep 29;375(13):1221-30
pubmed: 27571011
Eur Heart J. 2017 Jun 7;38(22):1756-1763
pubmed: 28379344
J Am Heart Assoc. 2021 Jan 5;10(1):e018108
pubmed: 33356406
Heart Rhythm. 2016 Feb;13(2):e50-86
pubmed: 26607062
Europace. 2016 Nov;18(11):1726-1734
pubmed: 26705555
Europace. 2011 Mar;13(3):389-94
pubmed: 21208947
Eur Heart J. 2015 Nov 1;36(41):2793-2867
pubmed: 26320108
J Am Coll Cardiol. 2012 Oct 23;60(17):1647-55
pubmed: 23021331
J Interv Card Electrophysiol. 2019 Apr;54(3):267-275
pubmed: 30523511
Circulation. 2009 Sep 8;120(10):835-42
pubmed: 19704100
Europace. 2013 Aug;15(8):1150-7
pubmed: 23407630
Ann Intern Med. 2012 Feb 7;156(3):195-203
pubmed: 22312139

Auteurs

Sem Briongos-Figuero (S)

Hospital Universitario Infanta Leonor Madrid Spain.
Universidad Complutense de Madrid Madrid Spain.

Arcadio García-Alberola (A)

Hospital Virgen de la Arrixaca Murcia Spain.

Jerónimo Rubio (J)

Hospital Clínico Universitario de Valladolid Valladolid Spain.

José María Segura (JM)

Hospital Reina Sofía de Córdoba Córdoba Spain.

Aníbal Rodríguez (A)

Hospital Universitario de Canarias Santa Cruz de Tenerife Spain.

Rafael Peinado (R)

Hospital Universitario La Paz Madrid Spain.

Javier Alzueta (J)

Hospital Universitario Virgen de la Victoria Málaga Spain.

José B Martínez-Ferrer (JB)

Hospital Universitario de Áraba Álava Spain.

Xavier Viñolas (X)

Hospital Santa Creu i Sant Pau Barcelona Spain.

Joaquín Fernández de la Concha (J)

Hospital Infanta Cristina Badajoz Spain.

Ignasi Anguera (I)

Hospital Universitario de Bellvitge Barcelona Spain.

María Martín (M)

Medtronic Ibérica Madrid Spain.

Laia Cerdá (L)

Medtronic Ibérica Madrid Spain.

Luisa Pérez (L)

Complexo Hospitalario Universitario de A Coruña A Coruña Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH